Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anzu Special Acquisition Corp I was a special purpose acquisition company (SPAC) sponsored by Anzu Partners, a venture capital firm specializing in industrial and life science technologies. The company completed its initial public offering in March 2021, raising approximately $420 million to target high-growth technology businesses. Its investment mandate specifically highlighted sectors such as life science tools, advanced materials, and industrial monitoring technologies. Throughout its operation, the SPAC sought to identify a target that demonstrated transformative potential within its core focus areas. However, due to unfavorable market conditions and the inability to finalize a suitable business combination, the company opted to liquidate. In March 2023, Anzu Special Acquisition Corp I redeemed its shares and ceased all operations, returning capital to its shareholders.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Anzu Special Acquisition Corp.